Corbus Pharmaceuticals Holdings, Inc. (CRBP)
2.06
-0.38
(-15.40%)
USD |
NASDAQ |
Nov 20, 16:00
2.05
-0.01
(-0.49%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Research and Development Expense (TTM) : 103.65M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 103.65M |
| June 30, 2026 | 90.26M |
| March 31, 2026 | 74.27M |
| December 31, 2025 | 70.10M |
| September 30, 2025 | 60.48M |
| June 30, 2025 | 50.42M |
| March 31, 2025 | 42.10M |
| December 31, 2024 | 32.22M |
| September 30, 2024 | 30.41M |
| June 30, 2024 | 26.16M |
| March 31, 2024 | 23.54M |
| December 31, 2023 | 31.17M |
| September 30, 2023 | 30.43M |
| June 30, 2023 | 27.99M |
| March 31, 2023 | 26.24M |
| December 31, 2022 | 16.14M |
| September 30, 2022 | 15.66M |
| June 30, 2022 | 20.25M |
| March 31, 2022 | 29.01M |
| December 31, 2021 | 36.45M |
| September 30, 2021 | 46.79M |
| June 30, 2021 | 65.62M |
| March 31, 2021 | 85.04M |
| December 31, 2020 | 98.27M |
| September 30, 2020 | 106.12M |
| Date | Value |
|---|---|
| June 30, 2020 | 100.75M |
| March 31, 2020 | 92.24M |
| December 31, 2019 | 90.08M |
| September 30, 2019 | 81.90M |
| June 30, 2019 | 72.55M |
| March 31, 2019 | 60.63M |
| December 31, 2018 | 48.61M |
| September 30, 2018 | 41.12M |
| June 30, 2018 | 33.93M |
| March 31, 2018 | 29.44M |
| December 31, 2017 | 26.04M |
| September 30, 2017 | 23.13M |
| June 30, 2017 | 21.83M |
| March 31, 2017 | 19.63M |
| December 31, 2016 | 15.44M |
| September 30, 2016 | 11.88M |
| June 30, 2016 | 9.199M |
| March 31, 2016 | 7.339M |
| December 31, 2015 | 5.889M |
| September 30, 2015 | 4.637M |
| June 30, 2015 | 3.455M |
| March 31, 2015 | 1.917M |
| December 31, 2014 | 1.256M |
| September 30, 2014 | 0.6687M |
| June 30, 2014 | 0.2451M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Heron Therapeutics, Inc. | 11.93M |
| Tonix Pharmaceuticals Holding Corp. | 80.40M |
| Karyopharm Therapeutics, Inc. | 120.81M |
| Minerva Neurosciences, Inc. | 19.77M |
| Ocugen, Inc. | 45.12M |